Management of refractory ulcerative colitis

  • Sunana Sohi
  • Russell D. Cohen
Article

Opinion statement

A physician’s approach to patients with ulcerative colitis (UC) who are refractory to standard first-line therapies must be thoughtful and systematic and include the individual’s physical and emotional state as the physician examines the various dietary, medical, and surgical options currently available. It is of foremost importance to confirm that the refractory patient’s symptoms are not simply due to dietary indiscretion, concomitant bowel infection (especially with Clostridium difficile), an incorrect diagnosis (eg, colitis due to infection, NSAIDs, ischemia, diverticulitis, or Crohn’s disease), or even a concomitant diagnosis (eg, celiac sprue, pancreatic insufficiency, functional bowel disorder, laxative or sorbitol intake). The ability to quickly assess the status of the colonic mucosa with flexible sigmoidoscopy aids in the ability to distinguish patients with refractory inflammation from those with other diagnoses. The initiation and optimization of the long-term purine analogues azathioprine (AZA) or 6-mercaptopurine (6-MP) remain the backbone of medical therapy for patients with refractory UC. For those unresponsive to corticosteroids, quicker induction of remission may necessitate infliximab, cyclosporine, or tacrolimus. Successful induction and maintenance with AZA, 6-MP, and/or infliximab should be followed by long-term therapy with these agents. Cessation of therapy often leads to relapse. Novel therapies under investigation hold the promise of offering more options for both the induction and maintenance of remission in refractory UC patients. Discussions of surgical intervention should not be put off as a last resort but rather included in the overall treatment plan offered to the patient.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Yang A, Chen Y, Scherl E, et al.: Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis 2005, 11:528–532.PubMedCrossRefGoogle Scholar
  2. 2.
    Ardizzone S, Molteni P, Imbesi V, et al.: Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997, 25:330–333.PubMedCrossRefGoogle Scholar
  3. 3.
    Fraser AG, Orchard TR, Jewell DP: The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485–489. Although a retrospective review, this is one of the largest, most comprehensive studies establishing a role for the purine analogues in the induction and maintenance of remission in IBD patients.PubMedCrossRefGoogle Scholar
  4. 4.
    Warman JI, Korelitz BI, Fleisher MR, Janardhanam R: Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn’s disease and ulcerative colitis. J Clin Gastroenterol 2003, 37:220–225.PubMedCrossRefGoogle Scholar
  5. 5.
    Matula S, Croog V, Itzkowitz S, et al.: Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005, 3:1015–1021.PubMedCrossRefGoogle Scholar
  6. 6.
    Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9–17. This is an important retrospective cohort study supporting the continuation of 6-MP therapy in female IBD patients who are pregnant or contemplating pregnancy.PubMedCrossRefGoogle Scholar
  7. 7.
    Dubinsky MC, Hassard PV, Seidman EG, et al.: An openlabel pilot study using thioguanine as a therapeutic alternative in Crohn’s disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001, 7:181–189. This is a pilot study of the successful use of thioguanine in patients previously intolerant or unresponsive to AZA or 6-MP. Subsequent findings of hepatotoxicity have limited use of this agent.PubMedCrossRefGoogle Scholar
  8. 8.
    Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298–303.PubMedCrossRefGoogle Scholar
  9. 9.
    Message L, Bourreille A, Laharie D, et al.: Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol Clin Biol 2005, 29:231–235.PubMedCrossRefGoogle Scholar
  10. 10.
    Rolny P, Sadik R: Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy. Int J Colorectal Dis 2002, 17:67–69.PubMedCrossRefGoogle Scholar
  11. 11.
    Campbell S, Travis S, Jewell D: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005, 17:79–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Actis GC, Lagget M, Rizzetto M, et al.: Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis [in Italian]. Minerva Med 2004, 95:65–70.PubMedGoogle Scholar
  13. 13.
    de Saussure P, Soravia C, Morel P, Hadengue A: Lowdose oral microemulsion ciclosporin for severe, refractory ulcerative colitis. Aliment Pharmacol Ther 2005, 22:203–208.PubMedCrossRefGoogle Scholar
  14. 14.
    Fellermann K, Tanko Z, Herrlinger KR, et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002, 8:317–324. This large study suggests equivalent efficacy between oral and intravenous dosing of tacrolimus in the treatment of refractory colitis.PubMedCrossRefGoogle Scholar
  15. 15.
    Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W: Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:415–423.PubMedCrossRefGoogle Scholar
  16. 16.
    Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201–1207. This pilot study suggests that whereas mycophenolate was effective in some patients with refractory colitis, the efficacy and safety were worse than in patients receiving standard AZA therapy.PubMedCrossRefGoogle Scholar
  17. 17.
    Ford AC, Towler RJ, Moayyedi P, et al.: Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:1365–1369.PubMedCrossRefGoogle Scholar
  18. 18.
    Skelly MM, Logan RF, Jenkins D, et al.: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:93–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Cummings JR, Herrlinger KR, Travis SP, et al.: Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005, 21:385–389.PubMedCrossRefGoogle Scholar
  20. 20.
    Te HS, Schiano TD, Kuan SF, et al.: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150–3156. This prospective study showed that routine liver biopsy is not warranted in IBD patients receiving a cumulative dose of MTX greater than 1500 g without other risk factors or signs of liver disease.PubMedCrossRefGoogle Scholar
  21. 21.
    Lichtenstein GR: Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001, 7:89–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Sands BE, Tremaine WJ, Sandborn WJ, et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7:83–88.PubMedCrossRefGoogle Scholar
  23. 23.
    Probert CS, Hearing SD, Schreiber S, et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52:998–1002.PubMedCrossRefGoogle Scholar
  24. 24.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462–2476. This is a combination of two large, randomized, placebocontrolled, multicenter, international trials establishing the efficacy of infliximab in the induction and maintenance of remission in patients with refractory UC.PubMedCrossRefGoogle Scholar
  25. 25.
    Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608. This analysis identifies that co-administration of AZA, 6-MP, or MTX results in lower rates and titers of anti-infliximab antibodies, fewer infusion reactions, and higher serum levels of infliximab.PubMedCrossRefGoogle Scholar
  26. 26.
    Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924. This randomized, placebo-controlled trial shows that the pre-administration of intravenous hydrocortisone (200 mg) before the initial infliximab infusion, and administration of a second infliximab infusion within 8 weeks of the first, results in lower levels of anti-infliximab antibodies and longer patient responses to therapy.PubMedCrossRefGoogle Scholar
  27. 27.
    Rubenstein JH, Chong RY, Cohen RD: Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002, 35:151–156. This is the initial study demonstrating substantial decrease in the utilization of health care resources in Crohn’s patients following initiation of infliximab therapy.PubMedCrossRefGoogle Scholar
  28. 28.
    Harrison J, Rubenstein J, Leff A, Cohen R: A controlled trial of the impact of infliximab upon health care utilization, costs, and charges in patients with Crohn’s disease [abstract]. Gastroenterology 2003, 124:A521.CrossRefGoogle Scholar
  29. 29.
    Jewell DP, Satsangi J, Lobo A, et al.: Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005, 17:1047–1052.PubMedCrossRefGoogle Scholar
  30. 30.
    Tulchinsky H, Hawley PR, Nicholls J: Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003, 238:229–234.PubMedGoogle Scholar
  31. 31.
    Meagher AP, Farouk R, Dozois RR, et al.: J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998, 85:800–803.PubMedCrossRefGoogle Scholar
  32. 32.
    Hurst RD: Surgical management of inflammatory bowel disease. In Inflammatory Bowel Disease: Diagnosis and Therapeutics. Edited by Cohen RD. Totowa, NJ: Humana Press; 2003:157–199.CrossRefGoogle Scholar
  33. 33.
    Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial. Gastroenterology 2003, 124:1202–1209. This randomized, double-blind, placebo-controlled trial showed that an initial bout of pouchitis can be prevented with prophylactic use of the probiotic cocktail VSL#3® immediately following surgery.PubMedCrossRefGoogle Scholar
  34. 34.
    Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305–309. The first convincing clinical trial establishing a role for probiotics in patients with IBD, this randomized, double-blind, placebo-controlled trial demonstrated that pouchitis relapse can be prevented with the use of VSL#3®.PubMedCrossRefGoogle Scholar
  35. 35.
    Leong AP, Londono-Schimmer EE, Phillips RK: Life-table analysis of stomal complications following ileostomy. Br J Surg 1994, 81:727–729.PubMedCrossRefGoogle Scholar
  36. 36.
    Bauer JJ, Gelernt IM, Salky B, Kreel I: Sexual dysfunction following proctocolectomy for benign disease of the colon and rectum. Ann Surg 1983, 197:363–367.PubMedCrossRefGoogle Scholar
  37. 37.
    Plevy S, Salzberg B, Regueiro M, et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe, steroid-refractory ulcerative colitis: preliminary results of a phase I study [abstract]. Gastroenterology 2003, 124:A-7.CrossRefGoogle Scholar
  38. 38.
    Gordon FH, Hamilton MI, Donoghue S, et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002, 16:699–705.PubMedCrossRefGoogle Scholar
  39. 39.
    Van Assche G, Van Ranst M, Sciot R, et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005, 353:362–368.PubMedCrossRefGoogle Scholar
  40. 40.
    Feagan BG, Greenberg GR, Wild G, et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499–2507.PubMedCrossRefGoogle Scholar
  41. 41.
    Musch E, Andus T, Malek M: Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther 2002, 16:1233–1239.PubMedCrossRefGoogle Scholar
  42. 42.
    Musch E, Andus T, Kruis W, et al.: Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005, 3:581–586.PubMedCrossRefGoogle Scholar
  43. 43.
    Tilg H, Vogelsang H, Ludwiczek O, et al.: A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003, 52:1728–1733.PubMedCrossRefGoogle Scholar
  44. 44.
    Kohgo Y, Hibi H, Chiba T, et al.: Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. Ther Apher 2002, 6:255–260.PubMedCrossRefGoogle Scholar
  45. 45.
    Hanai H, Watanabe F, Takeuchi K, et al.: Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Naganuma M, Funakoshi S, Sakuraba A, et al.: Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251–257.PubMedCrossRefGoogle Scholar
  47. 47.
    Kruis W, Dignass A, Steinhagen-Thiessen E, et al.: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005, 11:7001–7006.PubMedGoogle Scholar
  48. 48.
    Creed TJ, Norman MR, Probert CS, et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003, 18:65–75.PubMedCrossRefGoogle Scholar
  49. 49.
    Van Assche G, Dalle I, Noman M, et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 2003, 98:369–376.PubMedCrossRefGoogle Scholar
  50. 50.
    Vernia P, Annese V, Bresci G, et al.: Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Invest 2003, 33:244–248.PubMedCrossRefGoogle Scholar
  51. 51.
    Sinha A, Nightingale J, West KP, et al.: Epidermal growth factor enemas with oral mesalamine for mildto-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003, 349:350–357.PubMedCrossRefGoogle Scholar
  52. 52.
    Farrell RJ: Epidermal growth factor for ulcerative colitis. N Engl J Med 2003, 349:395–397.PubMedCrossRefGoogle Scholar
  53. 53.
    Borkow G, Leng Q, Weisman Z, et al.: Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000, 106:1053–1060.PubMedCrossRefGoogle Scholar
  54. 54.
    Summers RW, Elliott DE, Urban JF, et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825–832. This is a landmark randomized, placebo-controlled, pilot trial suggesting a potential therapeutic role for helminths in the treatment of UC.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2006

Authors and Affiliations

  • Sunana Sohi
  • Russell D. Cohen
    • 1
  1. 1.Department of Medicine, Section of GastroenterologyUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations